Results 101 to 110 of about 69,474 (260)

Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia

open access: yesOncogene, 2018
The poor outcomes in infant acute lymphoblastic leukemia (ALL) necessitate new treatments. Here we discover that EIF4E protein is elevated in most cases of infant ALL and test EIF4E targeting by the repurposed antiviral agent ribavirin, which has ...
K. Urtishak   +24 more
semanticscholar   +1 more source

EFFECT OF RIBAVIRIN ON VIRAL HEPATITIS IN LABORATORY ANIMALS [PDF]

open access: green, 1977
Robert W. Sidwell   +3 more
openalex   +1 more source

Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial

open access: yesAnnals of Hepatology, 2003
Treatment with polyethylene glycol-modified interferon alfa-2a (peginterferon) alone produces significantly higher sustained antiviral responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection.
Francisco Bosques-Padilla, MD   +7 more
doaj  

The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment

open access: yesDrug Safety, 2017
IntroductionSignificant teratogenic effects have been demonstrated in all animal species exposed to ribavirin. Ribavirin is prescribed for chronic hepatitis C and is contraindicated in women who are pregnant and in the male sexual partners of women who ...
S. Sinclair   +5 more
semanticscholar   +1 more source

Modeling Ribavirin‐Induced Anemia in Patients with Chronic Hepatitis C Virus

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2016
Ribavirin remains an important component of hepatitis C treatment in certain clinical scenarios, but it causes hemolytic anemia. A quantitative understanding of the ribavirin exposure‐anemia relationship is important in dose individualization ...
LS Wu   +4 more
doaj   +1 more source

Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin

open access: yesJournal of the Formosan Medical Association, 2020
Background/Purpose: The major dose-limiting toxicity of ribavirin is hemolytic anemia. We investigated the incidence, risk factors and impact on virological response of anemia in chronic hepatitis C genotype 2 patients receiving sofosbuvir plus ribavirin
Chi-Ching Chen   +10 more
doaj  

Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy

open access: yesBMC Infectious Diseases
Background Globally, 80 million people are suffering from chronic Hepatitis C virus (HCV) infection. Sofosbuvir ribavirin-based anti-HCV therapy is associated with anemia and other adverse effects.
Sameen Amjed   +6 more
doaj   +1 more source

Effect of Ribavirin and immune serum on Junin virus-infected primates [PDF]

open access: bronze, 1986
Mercedes Weissenbacher   +5 more
openalex   +1 more source

EFFECT OF RIBAVIRIN ON VIRAL TRANSCRIPTION [PDF]

open access: bronze, 1987
Philip Toltzis   +3 more
openalex   +1 more source

Home - About - Disclaimer - Privacy